Edition:
India

People: TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

3.85USD
11 Oct 2019
Change (% chg)

-- (--)
Prev Close
$3.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
869,395
52-wk High
$6.09
52-wk Low
$1.83

Musing, Jules 

Mr. Jules A. Musing is Independent Director of TherapeuticsMD, Inc., since May 16, 2013. He has served as a director of our company since May 2013. In the course of Mr. Musing’s 36-year career in the pharmaceutical and biotechnology industry, specifically at Johnson & Johnson and its affiliates, he has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. This included the establishment of new scientific, technology and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. Prior to moving into those roles, Mr. Musing was Vice President Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide from March 1982 to December 1984; President of Pitman-Moore, Inc., a U.S.-based Johnson & Johnson company from January 1985 to June 1987; Managing Director of Janssen Pharmaceutical in Portugal from July 1987 to March 1990; President of Serono, Inc. in the United States and Executive Vice President with responsibilities for North and South America from April 1990 to January 1993; Member of the board of directors of Ortho Biotech, Inc. from January 1993 to October 1999; and Managing Director of Ortho Biotech in France (a Johnson & Johnson affiliate) from October 1999 to January 2003. From January 2003 to his retirement in September 2010, Mr. Musing served as Vice President, Licensing and Acquisitions for the Pharmaceutical Group at Johnson & Johnson, where he was responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products in all therapeutic areas. He has served as a director of Delphi Digital, Inc. since March 2012 and Chairman of the Scientific Board of Advisors for Noble Capital Financial Markets since February 2012.

Basic Compensation

Total Annual Compensation, USD 65,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 180,039
Fiscal Year Total, USD 245,039

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tommy Thompson

378,308

John Milligan

1,701,430

Robert Finizio

2,724,580

Brian Bernick

1,297,940

Daniel Cartwright

1,245,480

Michael Donegan

703,480
As Of  31 Dec 2018